Treatment and prevention of influenza in geriatric patients

References

• Centers for Disease Control and Prevention. Pink Book – influenza. [updated 2021 Aug18; cited 2023 Apr 20]. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/flu.html
   Google Scholar
• History.com Editors. Influenza. [updated 2020 Feb 5; cited 2023 Apr 20]. Available from: https://www.history.com/topics/inventions/flu
   Google Scholar
• Dambaugh LA. A review of influenza, implications for the geriatric population. Crit Care Nurse Clin N Am. 2012;24(4):573–580. doi: 10.1016/j.ccell.2012.07.005
   PubMed Web of Science ®Google Scholar
• Chairat K, Tarning J, White NJ, et al. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J Clin Pharmacol. 2012;53(2):119–139. doi: 10.1177/0091270012440280
   Web of Science ®Google Scholar
• Uyeki TM, Hui DS, Zambon M, et al. Influenza. Lancet. 2022;400(10353):693–706. doi: 10.1016/S0140-6736(22)00982-5
   PubMed Web of Science ®Google Scholar
• Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2):020421. doi: 10.7189/jogh.09.020421
   PubMed Web of Science ®Google Scholar
• Watson A, Wilkinson TMA. Respiratory viral infections in the elderly. Ther Adv Respir Dis. 2021;15:1–17. doi: 10.1177/1753466621995050
   Web of Science ®Google Scholar
• Langer J, Welch VL, Moran MM, et al. High clinical burden of influenza disease in adults aged ≥ 65 years: can we do better? A systematic literature review. Adv Ther. 2023;40(4):1601–1627. doi: 10.1007/s12324-023-02432-1
   PubMedGoogle Scholar
• Centers For Disease Control and Prevention. Information for clinicians on influenza virus testing. [updated 2022 Aug 29; cited 2023 Apr 18]. Available from: https://www.cdc.gov/flu/professionals/diagnosis/index.htm
   Google Scholar
• The Noun Project. [updated 2023 Jun 27; cited 2023 Jul 20] Available from: https://thenounproject.com/
   Google Scholar
• Koren G, Nordon G, Radinsky K, et al. Clinical pharmacology of old age. Expert Rev Clin Pharmacol. 2019;12(8):749–755. doi: 10.1080/17512433.2019.1632188
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC seasonal flu vaccine effectiveness studies 2022. [updated 2022Dec 22; cited 2023 Apr 18]. Available from: https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm
   Google Scholar
• Beran J, Reynales H, Poder A, et al. Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomized, controlled, multicentre, phase 3 efficacy study. Lancet Infect Dis. 2021;21(7):1027–1037. doi: 10.1016/S1473-3099(20)30694-0
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Flu & People 65 years and older. [updated 2022 Aug 25;cited 2023 Apr 18]. Available from: https://www.cdc.gov/flu/highrisk/65over.htm
   Google Scholar
• Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices — United States, 2022–23 influenza season. MMWR Recomm Rep. 2022;71(1):1–28. doi: 10.15585/mmwr.rr7101a1
   PubMedGoogle Scholar
• FLUAD Quadrivalent (Influenza Vaccine, Adjuvanted) Summary of Product Characteristics. Seqirus USA Inc. Summit (NJ);Jul 2022.
   Google Scholar
• Boikos C, Fischer L, O’Brien D, et al. Relative effectiveness of adjuvanted trivalent inactivated influenza vaccine versus egg-derived quadrivalent inactivated influenza vaccines and high-dose trivalent influenza vaccine in preventing influenza-related medical encounters in US adults ≥ 65 years during the 2017-2018 and 2018-2019 influenza seasons. Clin Infect Dis. 2021;73(5):816–823. doi: 10.1093/cid/ciab152
   PubMed Web of Science ®Google Scholar
• Boikos C, Imran M, Nguyen VH, et al. Effectiveness of the adjuvanted influenza vaccine in older adults at high risk of influenza complications. Vaccines. 2021;9(8):862. doi: 10.3390/vaccines9080862
   Web of Science ®Google Scholar
• Lapi F, Marconi E, Simonetti M, et al. Adjuvanted versus nonadjuvanted influenza vaccine and risks of hospitalizations for pneumonia and cerebro-cardiovascular events in the elderly. Expert Review Of Vaccines. 2019;18(6):663–670. doi: 10.1080/14760584.2019.1622418
   PubMed Web of Science ®Google Scholar
• Cowling BJ, Perera BA, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clinical Infectious Diseases. 2020;71(7):1704–1714. doi: 10.1093/cid/ciz1034
   PubMed Web of Science ®Google Scholar
• Tamiflu (oseltamivir phosphate) Summary of Product Characteristics. Genentech Inc. South San Francisco (CA);Jun 2016.
   Google Scholar
• Relenza (Zanamivir) Inhalation Powder. Summary of product characteristics. GlaxoSmithKline (NC): Research Triangle Park; 2011 Dec.
   Google Scholar
• Dectova (Zanamivir). Summary of Product Characteristics. GlaxoSmithKline Manufacturing. Parma Italy: S.P.A; Aug 2021.
   Google Scholar
• Rapivab (Peramivir). Summary of Product Characteristics. BioCryst Pharmaceuticals. Durham (NC): Inc; 2022 Nov.
   Google Scholar
• Xofluza (baloxavir marboxil). Summary of Product Characteristics. Genentech USA, Inc, South San Francisco (CA). Aug 2022
   Google Scholar
• Zheng L, Han Y, Guan Y, et al. Risks in clinical applications of oseltamivir phosphate in the real world. Pharmazie. 2020;75(6):284–287. doi: 10.1691/ph.2020.0352
   PubMed Web of Science ®Google Scholar
• Massarella JW, He GZ, Door A, et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in health adult and elderly volunteers. The Journal Of Clinical Pharmacology. 2000;40(8):836–843. doi: 10.1177/00912700022009567
   PubMed Web of Science ®Google Scholar
• Abe M, Smith J, Urae A, et al. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann Pharmacother. 2006;40(10):1724–1730. doi: 10.1345/aph.1H174
   PubMed Web of Science ®Google Scholar
• Kamal MA, Van Wart SA, Rayner CR, et al. Population pharmacokinetics of oseltamivir: pediatrics through geriatrics. Antimicrob Agents Chemother. 2013;57(8):3470–3477. doi: 10.1128/AAC.02438-12
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Ishibashi T, Hollister AS, et al. Population pharmacokinetics of peramivir in healthy volunteers and influenza patients. Antimicrob Agents Chemother. 2015;59(11):6755–6762. doi: 10.1128/AAC.00799-15
   PubMed Web of Science ®Google Scholar
• Choi WK, Ryu SY, Lee J, et al. Safety and effectiveness of peramivir in Korean adult influenza patients: prospective observational study based on post-marketing surveillance data. J Korean Med Sci. 2018;33(32):e212. doi: 10.3346/jkms.2018.33.e212
   PubMed Web of Science ®Google Scholar
• Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors. J Infect Chemother. 2016;22(10):677–684. doi: 10.1016/j.jiac.2016.07.004
   PubMed Web of Science ®Google Scholar
• Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation. J Infect Chemother. 2014;20(11):689–695. doi: 10.1016/j.jiac.2014.07.006
   PubMed Web of Science ®Google Scholar
• Nayoung H, Oh JM, Kim IW. Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews. Sci Rep. 2020;10(1):3116. doi: 10.1038/s41598-020-60068-5
   PubMed Web of Science ®Google Scholar
• Ishizuka H, Yoshiba S, Yoshihara K, et al. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958. J Clin Pharmacol. 2011;51(2):243–251. doi: 10.1177/0091270010361914
   PubMed Web of Science ®Google Scholar
• Ishizuka H, Toyama K, Yoshiba S, et al. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. Antimicrob Agents Chemother. 2012;56(7):3873–3878. doi: 10.1128/AAC.06456-11
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Ishizuka H, Kubo Y. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. Drug Metab Pharmacokinet. 2013;28(5):416–426. doi: 10.2133/dmpk.DMPK-12-RG-115
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Kawai N, Iwaki N, et al. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011–2012 to 2014–2015. J Infect Chemother. 2016;22(9):605–610. doi: 10.1016/j.jiac.2016.06.003
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Kawai N, Iwaki N, et al. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons. J Infect Chemother. 2017;23(9):627–633. doi: 10.1016/j.jiac.2017.06.008
   PubMed Web of Science ®Google Scholar
• Koshimichi H, Tsuda Y, Ishibashi T, et al. Population pharmacokinetic and exposure-response analyses of baloxavir mrboxil in adults and adolescents including patients with influenza. J Pharm Sci. 2019;108(5):1896–1904. doi: 10.1016/j.xphs.2018.12.005
   PubMed Web of Science ®Google Scholar
• Koshimichi H, Retout S, Cosson V, et al. Population pharmacokinetics and exposure-response relationships of baloxavir marboxil in influenza patients at high risk of complications. Antimicrob Agents Chemother. 2020;64(7):e00119–20. doi: 10.1128/AAC.00119-20
   PubMed Web of Science ®Google Scholar
• Dufrasne F. Baloxavir marboxil: an original new drug against influenza. Pharmaceuticals (Basel). 2021;15(1):28. doi: 10.3390/ph15010028
   PubMedGoogle Scholar
• Tejada S, Tejo AM, Pena-Lopez Y, et al. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(7):901–918. doi: 10.1080/17512433.2021.1917378
   PubMed Web of Science ®Google Scholar
• Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204–1214. doi: 10.1016/S1473-3099(20)30004-9
   PubMed Web of Science ®Google Scholar
• Liu JW, Lin SH, Wang LC, et al. Comparison of antiviral agents for seasonal influenza outcomes in healthy adults and children: a systematic review and network meta-analysis. JAMA Netw Open. 2021;4(8):e2119151. doi: 10.1001/jamanetworkopen.2021.19151
   PubMed Web of Science ®Google Scholar
• Dziewiatkowski NA, Osmon EN, Chahine EB, et al. Baloxavir: A novel single-dose oral antiviral for the treatment of influenza. Sr Care Pharm. 2019;34(4):243–252. doi: 10.4140/TCP.n.2019.243
   PubMed Web of Science ®Google Scholar
• Abraham GM, Morton JB, Saravolatz LD. Baloxavir: a novel antiviral agent in the treatment of influenza. Clin Infect Dis. 2020;71(7):1790–1794. doi: 10.1093/cid/ciaa107
   PubMed Web of Science ®Google Scholar
• Kumar D, Ison MG, Mira JP, et al. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalized with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis. 2022;22(5):718–730. doi: 10.1016/S1473-3099(21)00469-2
   PubMed Web of Science ®Google Scholar
• Butler CC, van der Velden AW, Bongard E, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomized controlled trial. Lancet. 2020;395(10217):42–52. doi: 10.1016/S0140-6736(19)32982-4
   PubMed Web of Science ®Google Scholar
• Bulloch M, Hartley C, Elston R. 674: evaluation of clinical trials including geriatrics for treatment and prophylaxis of influenza. Crit Care Med. 2021;49(1):332. doi: 10.1097/01.ccm.0000728584.53459.49
   Web of Science ®Google Scholar
• Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc. 2005;6(6):359–366. doi: 10.1016/j.jamda.2005.08.006
   PubMedGoogle Scholar
• Seale H, Weston KM, Dwyer DE, et al. The use of oseltamivir during an influenza B outbreak in a chronic care hospital. Influenza Other Respir Viruses. 2009;3(1):15–20. doi: 10.1111/j.1750-2659.2008.00063.x
   PubMed Web of Science ®Google Scholar
• Dronavalli M, Lord H, Alexander K, et al. Effectiveness of oseltamivir prophylaxis in influenza outbreaks in residential aged care. J Epidemiol Glob Health. 2020;10(2):184–189. doi: 10.2991/jegh.k.200402.001
   PubMed Web of Science ®Google Scholar
• Ye M, Jacobs A, Khan M, et al. Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis. BMJ Open. 2016;6(7):e011686. doi: 10.1136/bmjopen-2016-011686
   PubMed Web of Science ®Google Scholar
• Rainwater-Lovett K, Chun K, Lessler J. Influenza outbreak control practices and the effectiveness of interventions in long-term care facilities: a systematic review. Influenza Other Respir Viruses. 2014;8(1):74–82. doi: 10.1111/irv.12203
   PubMed Web of Science ®Google Scholar
• Lytras T, Mouratidou E, Andreopoulou A, et al. Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multiseason cohort study. Clin Infect Dis. 2019;69(11):1896–1902. doi: 10.1093/cid/ciz101
   PubMed Web of Science ®Google Scholar
• Soldevila N, Toedo D, de Lajarazu O, et al. Effect of antiviral treatment in older patients hospitalized with confirmed influenza. Antiviral Res. 2020;178:104785.
   PubMed Web of Science ®Google Scholar
• Adlhoch C, Delgado-Sanz C, Carnahan A, et al. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalized influenza patients, surveillance data from 11 EU countries, 2010 to 2020. Euro Surveill. 2023;28(4):ii=2200340. doi: 10.2807/1560-7917.ES.2023.28.4.2200340
   Google Scholar
• Kositpantawong N, Surasombatpattana S, Siripaitoon P, et al. Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia. PLoS One. 2021;16(12):e0261411. doi: 10.1371/journal.pone.0261411
   PubMed Web of Science ®Google Scholar
• Lee SH, Kang HR, Jung JW, et al. Effect of oseltamivir on bleeding risk associated with warfarin therapy: a retrospective review. Clin Drug Investig. 2012;32(2):131–137. doi: 10.2165/11595860-000000000-00000
   PubMed Web of Science ®Google Scholar
• Davies BE, Baldo PA, Lennon-Chrimes S, et al. Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients. Br J Clin Pharmacol. 2010;70(6):834–843. doi: 10.1111/j.1365-2125.2010.03780.x
   PubMed Web of Science ®Google Scholar
• Smith KR, Bryan WE, Townsend ML, et al. Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy. J Thrombosis Thrombolysis. 2020;50(2):452–456. doi: 10.1007/s11239-019-02016-3
   PubMed Web of Science ®Google Scholar
• Mosholder AD, Racoosin JA, Young S, et al. Bleeding events following concurrent use of warfarin and oseltamivir by Medicare beneficiaries. Ann Pharmacother. 2013;47(11):1420–1248. doi: 10.1177/1060028013500940
   PubMed Web of Science ®Google Scholar
• Wang CB, Chiu ML, Lin PC, et al. Prompt oseltamivir therapy reduces medical care and mortality for patients with influenza infection, an Asian population cohort study. Medicine. 2015;94(27):1–6. doi: 10.1097/MD.0000000000001070
   PubMed Web of Science ®Google Scholar
• Hernu R, Chroboczek T, Madelaine T, et al. Early oseltamivir therapy improves the outcome in critically ill patients with influenza; a propensity analysis. Intensive care Med. 2019;44(2):257–260. doi: 10.1007/s00134-017-4953-3
   Web of Science ®Google Scholar
• Sharma Y, Horwood C, Hakendorf P, et al. Effectiveness of oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients. Int J Inf Dis. 2021;104:232–238. doi: 10.1016/j.ijid.2021.01.011
   PubMed Web of Science ®Google Scholar
• Khoury J, Szwarcwort M, Kra-Oz Z, et al. Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study. Eur J Clin Microbiol Infect Dis. 2017;37(2):319–323. doi: 10.1007/s10096-017-3135-0
   PubMed Web of Science ®Google Scholar
• Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomized controlled trials. Lancet. 2015;385(9979):1729–1737. doi: 10.1016/S0140-6736(14)62449-1
   PubMed Web of Science ®Google Scholar
• Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. Clin Ther. 2007;29(10):2246–2555. doi: 10.1016/j.clinthera.2007.10.001
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Sung I, Suter P, et al. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Cur Med Res Opin. 2005;21(5):761–768. doi: 10.1185/030079905X46214
   PubMed Web of Science ®Google Scholar
• Lee N, Hui DSC, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Inf Dis. 2013;57(11):1511–1519. doi: 10.1093/cid/cit597
   PubMed Web of Science ®Google Scholar
• Ishaqui A, Kan AH, Sulaiman SA, et al. Comparative efficacy assessment of antiviral alone and antiviral-antibiotic combination in prevention of influenza-B infection associated complications. Expert Rev Anti Infect Ther. 2021;19(9):1165–1173. doi: 10.1080/14787210.2021.1889369
   PubMed Web of Science ®Google Scholar
• Ishaqui AA, Khan AH, Sulaiman SA, et al. Efficacy comparison of oseltamivir alone and oseltamivir-antibiotic combination for early resolution of symptoms of severe influenza-A and influenza-B hospitalized patients. Saudi Med J. 2020;41(9):1015–1021. doi: 10.15537/smj.2020.9.25249
   PubMed Web of Science ®Google Scholar
• Kakeya H, Seki M, Izumikawa K, et al. Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. PLoS One. 2014;9(3):e91293. doi: 10.1371/journal.pone.0091293
   PubMed Web of Science ®Google Scholar
• Hayden FG, Atmar L, Schilling M, et al. Use of selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Eng J Med. 1999;341(18):1366–1343. doi: 10.1056/NEJM199910283411802
   Web of Science ®Google Scholar
• Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts a randomized controlled trial. JAMA. 2001;285(6):748–754. doi: 10.1001/jama.285.6.748
   PubMed Web of Science ®Google Scholar
• Carrat F, Duval X, Tubach F, et al. Effect of oseltamivir, zanamivir or oseltamivir– zanamivir combination treatments on transmission of influenza in households. Antivir Ther. 2012;17(6):1085–1090. doi: 10.3851/IMP2128
   PubMed Web of Science ®Google Scholar
• Ison MG, Szakaly P, Shapira M, et al. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant patients. Antivir Ther. 2012;17(6):955–965. doi: 10.3851/IMP2192
   PubMed Web of Science ®Google Scholar
• Peters PH, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001;49(8):1025–1031. doi: 10.1046/j.1532-5415.2001.49204.x
   PubMed Web of Science ®Google Scholar
• Vander Sande MA, Meijer A, Sen-Kerpicklik S, et al. Effectiveness of post-exposition prophylaxis with oseltamivir in nursing homes: a randomised controlled trial over four seasons. Emerg Themes Epidemiol. 2014;11(1):13. doi: 10.1186/1742-7622-11-13
   PubMedGoogle Scholar
• Shijubo N, Yamada G, Takahashi M, et al. Experience with oseltamivir in the control of nursing home influenza a outbreak. Intern Med. 2002;41(5):366–370. doi: 10.2169/internalmedicine.41.366
   PubMed Web of Science ®Google Scholar
• Lan CC, Liu CC, Chen YS. Acute exacerbation of psychiatric symptoms during influenza treatment with oseltamivir in chronic schizophrenia. J Chin Med Assoc. 2015;78(6):374–376. doi: 10.1016/j.jcma.2014.05.017
   PubMed Web of Science ®Google Scholar
• Kohen I. Oseltamivir-induced delirium in a geriatric patient. Int J Geriatr Psychiatry. 2007;22(9):930–936. doi: 10.1002/gps.1838
   PubMed Web of Science ®Google Scholar
• Gravenstein S, Johnston SL, Loeschel E, et al. Zanamivir, a review of clinical safety in individuals at high risk of developing influenza-related complications. Drug Saf. 2001;24(15):1113–1115. doi: 10.2165/00002018-200124150-00003
   PubMed Web of Science ®Google Scholar
• Wieringa A, Ter Horst PG, Wagenvoort GH, et al. Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration. Antivir Ther. 2023;28(1):13596535221150746. doi: 10.1177/13596535221150746
   Web of Science ®Google Scholar
• Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people’s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ. 2001;322(7286):577–579. doi: 10.1136/bmj.322.7286.577
   PubMedGoogle Scholar
• LaForce C, Man CY, Henderson FW, et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2007;29(8):1579–1590. doi: 10.1016/j.clinthera.2007.08.023
   PubMed Web of Science ®Google Scholar
• Lalezari J, Capion K, Keene O, et al. Zanamivir for the treatment of Influenza a and B infection in high-risk patients, a pooled analysis of randomized controlled trials. Arch Intern Med. 2001;161(2):212–217. doi: 10.1001/archinte.161.2.212
   PubMedGoogle Scholar
• Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infection. 2000;40(1):42–48. doi: 10.1053/jinf.1999.0602
   PubMed Web of Science ®Google Scholar
• The MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza a and B virus infections. Lancet. 1998;352(9144):1877–1881. doi: 10.1016/S0140-6736(98)10190-3
   PubMed Web of Science ®Google Scholar
• Cole JA, Loughlin JE, Ajene AA, et al. The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Clin Ther. 2002;24(11):1824–1839. doi: 10.1016/S0149-2918(02)80082-0
   PubMed Web of Science ®Google Scholar
• Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza a and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44(suppl_2):23–29. doi: 10.1093/jac/44.suppl_2.23
   PubMedGoogle Scholar
• Monto AS, Moult AB, Sharp SJ. Effect of zanamivir on duration and resolution of influenza symptoms. Clin Ther. 2000;22(11):1294–1305. doi: 10.1016/S0149-2918(00)83026-X
   PubMed Web of Science ®Google Scholar
• Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalized patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. The Lancet Respiratory Medicine. 2017;5(2):135–146. doi: 10.1016/S2213-2600(16)30435-0
   PubMed Web of Science ®Google Scholar
• Kaiser L, Henry D, Flack NP. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Inf Dis. 2000;30(3):587–589. doi: 10.1086/313696
   PubMed Web of Science ®Google Scholar
• Ambrozaitis A, Gravenstein S, van Essen GA, et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc. 2005;6(6):367–374. doi: 10.1016/j.jamda.2005.08.007
   PubMedGoogle Scholar
• Hirji Z, O’Grady S, Bonham J, et al. Utility of zanamivir for chemoprophylaxis of concomitant influenza a and B in a complex continuing care population. Infect Control Hosp Epidemiol. 2022;23(10):604–608. doi: 10.1086/501979
   Google Scholar
• Loughlin JE, Alfredson TD, Ajene AN, et al. Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. Clin Ther. 2002;24(11):1786–1799. doi: 10.1016/S0149-2918(02)80079-0
   PubMed Web of Science ®Google Scholar
• Su HC, Feng IJ, Tang HJ, et al. Comparative effectiveness of neuraminidase inhibitors in patients with influenza: a systemic review and network meta-analysis. J Infect Chemother. 2022;28(2):158–169. doi: 10.1016/j.jiac.2021.11.014
   PubMed Web of Science ®Google Scholar
• Hata A, Akashi-Ueda R, Takamatsu K, et al. Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther. 2014;8:2017–2038. doi: 10.2147/DDDT.S46654
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Z, Li X, et al. In vitro evaluation of absorption characteristics of peramivir for oral delivery. Eur J Drug Metab Pharmacokine. 2017;42(5):757–765. doi: 10.1007/s13318-016-0390-x
   PubMed Web of Science ®Google Scholar
• Funatsu Y, Tasaka S, Asami T, et al. Pharmacokinetics of intravenous peramivir in the airway epithelial lining fluid of healthy volunteers. Antivir Ther. 2016;21(7):621–625. doi: 10.3851/IMP3096
   PubMed Web of Science ®Google Scholar
• Takamatsu K, Marumo S, Fukui, et al. Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease. J. 2017;50(4):541–544. doi: 10.1016/j.jmii.2016.11.006
   Google Scholar
• Yoo JW, Choi SH, Huh JW, et al. Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza. J Med Virol. 2015;87(10):1649–1655. doi: 10.1002/jmv.24232
   PubMed Web of Science ®Google Scholar
• Nakamura S, Miyazaki T, Izumikawa K, et al. Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with Influenza a and B viruses: a multicenter randomized controlled study. Open Forum Infect Dis. 2017;4(3):ofx129. doi: 10.1093/ofid/ofx129
   PubMed Web of Science ®Google Scholar
• Lee JS, Lee MS, Park Y, et al. Clinical effectiveness of intravenous peramivir versus oseltamivir for the treatment of influenza in hospitalized patients. Infect Drug Resist. 2020;13:1479–1484.
   PubMed Web of Science ®Google Scholar
• Yeh CY, Wang FD, Chuang YC, et al. Clinical outcomes and prognostic factors of patients with severe influenza receiving intravenous peramivir salvage therapy in intensive care units. J Microbiol Immunol Infect. 2018;51(6):697–704. doi: 10.1016/j.jmii.2017.06.001
   PubMedGoogle Scholar
• Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of Influenza a and B viruses infection in high-risk patients. Antimicrob Agents Chemother. 2011;55(6):2803–2812. doi: 10.1128/AAC.01718-10
   PubMed Web of Science ®Google Scholar
• Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. 2014;19(4):349–361. doi: 10.3851/IMP2680
   PubMed Web of Science ®Google Scholar
• De Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis. 2014;59(12):e172–185. doi: 10.1093/cid/ciu632
   PubMed Web of Science ®Google Scholar
• Higashiguchi M, Matsumoto T, Fujii T. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza. Antivir Ther. 2018;23(2):157–165. doi: 10.3851/IMP3189
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011;9(10):851–857. doi: 10.1586/eri.11.112
   PubMed Web of Science ®Google Scholar
• Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antiviral Chem Chemother. 2010;21(2):71–84. doi: 10.3851/IMP1688
   PubMedGoogle Scholar
• Kashiwagi S, Watanabe A, Ikematsu H, et al. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. J Infect Chemother. 2013;19(4):740–749. doi: 10.1007/s10156-013-0622-9
   PubMed Web of Science ®Google Scholar
• Kashiwagi S, Watanabe A, Ikematsu H, et al. Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza. Clin Infect Dis. 2016 Aug 1;63(3):330–337. doi: 10.1093/cid/ciw255
   PubMed Web of Science ®Google Scholar
• Kashiwagi S, Yoshida S, Yamaguchi H, et al. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance. Int J Antimicrob Agents. 2012;40(5):381–388. doi: 10.1016/j.ijantimicag.2012.06.017
   PubMed Web of Science ®Google Scholar
• Nakano T, Okumura A, Tanabe T, et al. Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance. Scand J Infect Dis. 2013;45(6):469–477. doi: 10.3109/00365548.2012.763104
   PubMed Web of Science ®Google Scholar
• Tochino Y, Fujioka M, Sakazaki H, et al. Current usage and effectiveness of influenza medications and factors regarding the time taken to alleviate fever based on postcard questionnaire survey. J Gen Fam Med. 2017;18(6):386–392. doi: 10.1002/jgf2.109
   PubMedGoogle Scholar
• Lee J, Park JH, Kwa H, et al. Comparison of efficacy of intravenous peramivir and oral oseltamivir for the treatment of influenza: systematic review and meta-analysis. Yonsei Med J. 2017;58(4):778–785. doi: 10.3349/ymj.2017.58.4.778
   PubMed Web of Science ®Google Scholar
• Komeda T, Takazono T, Hosogaya N, et al. Comparison of hospitalization incidence in influenza outpatients treated with baloxavir marboxil or neuraminidase inhibitors: a health insurance claims database study. Clin Infect Dis. 2021;73(5):e1181–e1190. doi: 10.1093/cid/ciaa1870
   PubMed Web of Science ®Google Scholar
• Neuberger E, Wallick C, Chawla D, et al. Baloxavir vs oseltamivir: reduced utilization and costs in influenza. Am J Manag Care. 2022;28:e88–e95.
   PubMed Web of Science ®Google Scholar
• Shah S, McManus D, Bejou N, et al. Clinical outcomes of baloxavir versus oseltamivir in patients hospitalized with influenza a. J Antimicrob Chemother. 2020;75(10):3015–3022. doi: 10.1093/jac/dkaa252
   PubMed Web of Science ®Google Scholar
• Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020 Jul 23;383(4):309–320. doi: 10.1056/NEJMoa1915341
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. E7 studies in support of special populations; geriatrics’ questions and answers. Food and drug administration web site. [updated 24 Aug 2018; cited 2023 Apr 17]. Available from: https://cacmap.fda.gov/regulatory-information/search-fda-guidance-documents/e7-studies-support-special-populations-geriatrics-questions-and-answers
   Google Scholar
• U.S. National Library of Medicine. Baloxavir and oseltamivir for the treatment of severe influenza infection in immunocompromised patients. NCT04712539. [updated 2023 Apr 3; cited 2023 Apr 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT04712539?term=oseltamivir&recrs=abd&draw=2&rank=7
   Google Scholar
• U.S. National Library of Medicine. Baloxavir versus oseltamivir for nursing home influenza outbreaks. NCT05012189. [updated 2023 Mar 15; cited 2023 Apr 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT05012189?cond=baloxavir&draw=2&rank=1
   Google Scholar
• U.S. National Library of Medicine. Combination therapy with baloxavir and oseltamivir 1 for hospitalized patients with influenza (The COMBO Trial 1) (COMBO 1). NCT04327791. [updated 2023 Mar 9; cited 2023 Apr 18] Available from: https://clinicaltrials.gov/ct2/show/NCT04327791?recrs=abdef&cond=baloxavir&draw=3&rank=4
   Google Scholar